COMMUNIQUÉS West-GlobeNewswire

Olema Oncology Appoints Jason O’Byrne as Chief Financial Officer
13/08/2026
SAN FRANCISCO, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and [...]
Aveanna Healthcare Holdings Announces Second Quarter Financial Results and Revised 2026 Guidance
13/08/2026
Second Quarter Revenue was $670.5 million, a 13.7% increase over the prior year period Second Quarter Net income was $40.3 million compared to $27.0 million for the prior year period Adjusted EBITDA for Q2 2026 was $95. [...]
Montauk Brewing Company Announces New Collaboration with Morning Brew Inc.
13/08/2026
The Morning Brew, a Blonde Ale featuring Roasted Coffee Beans, is on tap now MONTAUK, N.Y., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Montauk Brewing Company , the coastal lifestyle brand by Tilray Brands, Inc. (NASDAQ: TLRY [...]
Vireo Growth Inc. Announces Share Buyback Program
13/08/2026
MINNEAPOLIS, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Vireo Growth Inc. ("Vireo" or the "Company") (CSE: VREO; OTCQX: VREOF), a leading vertically integrated cannabis company and agricultural markets platform, today announced [...]
ApolloMD Names Brianna Watson 2026 Emergency Medicine Scholarship Winner
13/08/2026
Howard University medical student receives $5,000 award for essay on technology, environmental health and emergency medicine ATLANTA, Aug. 13, 2026 (GLOBE NEWSWIRE) -- ApolloMD has named Brianna Watson, a fourth-year [...]
Zelluna ASA: Invitation to Second Quarter 2026 Results Webcast Presentation
13/08/2026
Oslo, Norway, 13 August 2026 – Zelluna (OSE: ZLNA), a company pioneering allogeneic “off-the-shelf” T-cell receptor-based natural killer (TCR-NK) therapies for the treatment of cancer, invites to a webcast presentation [...]
Bluejay Diagnostics Reports Q2 2026 Results; Strengthened Balance Sheet Supports Advancement of Symphony™ IL-6 Toward Regulatory Submission and Commercialization
13/08/2026
SYMON-II pivotal clinical study completes targeted enrollment of 750 patients Company advances toward planned 510(k) submission and commercialization with US manufacturing contract signed to mitigate supply-chain risk [...]
Vistin Pharma ASA: Invitation to Q2 2026 conference call
13/08/2026
Oslo, Norway, 13 August 2026 Vistin Pharma ASA (VISTN) will release its second quarter and YTD 2026 results on Thursday 20th of August 2026. Vistin Pharma will host a conference call for all shareholders and other [...]
Valneva Reports Half Year 2026 Financial Results and Provides Corporate Updates
13/08/2026
Total product sales of €64.0 million In-line with expectations; full-year guidance of €135 -150 million reaffirmed Solid cash position of €121.5 million as of end June 2026 Reflects disciplined cash management and [...]
Valneva publie ses résultats financiers du premier semestre 2026 et fait un point sur ses activités
13/08/2026
Ventes totales de produits de 64,0 millions d’euros o En ligne avec les attentes ; confirmation de la prévision annuelle de ventes comprises entre 135 et 150 millions d’euros. Solide position de trésorerie de 121,5 [...]
Zealand Pharma Announces Financial Results for the First Half of 2026
13/08/2026
Company announcement – No. 39 / 2026 Zealand Pharma Announces Financial Results for the First Half of 2026 A landmark first half defined by key milestones delivered for leading obesity assets, and a continued momentum [...]
Pharming announces commercial launch of Joenja (leniolisib) in Japan for adult and pediatric patients with APDS aged 4 and older
13/08/2026
Launch marks first commercial availability of Joenja® (leniolisib) for children aged 4 to 11 worldwide OrphanPacific, Inc. serves as Marketing Authorization holder and is responsible for supply and distribution in Japan [...]
Kuros Biosciences delivers 45% H1 2026 year-over-year sales growth and increases overall profitability
13/08/2026
Ad-hoc announcement pursuant to Article 53 of the SIX listing rules Kuros Biosciences delivers 45% H1 2026 year-over-year sales growth and increases overall profitability Schlieren (Zurich), Switzerland, August 13, 2026 [...]
Outlook Therapeutics Announces Pricing of $55.0 Million Public Offering of Common Stock and Warrants
13/08/2026
ISELIN, N.J., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (“Outlook Therapeutics”), a biopharmaceutical company focused on the development and commercialization of LYTENAVA™ (bevacizumab- [...]
Belite Bio Reports Unaudited Second Quarter 2026 Financial Results and Provides a Corporate Update
13/08/2026
U.S. Food and Drug Administration (FDA) accepted the New Drug Application (NDA) with Priority Review for tinlarebant for the treatment of Stargardt disease type 1 (STGD1); Prescription Drug User Fee Act (PDUFA) target [...]
NOTICE TO DISREGARD -- Leading Edge Health Inc
13/08/2026
LAS VEGAS, Aug. 12, 2026 (GLOBE NEWSWIRE) -- We are advised by VITALIBOOST LLC that journalists and other readers should disregard the news release, “Load Boost: Semenax, Volume Pills or SemEnhance - Which is Best Load [...]
NurExone Announces Binding MOU with Made Scientific for U.S. GMP Manufacturing and Commercial Supply Partnership
12/08/2026
The Signed MOU Targets Initial GMP Exosome Batches in H1 2027 to Support NurExone’s Clinical Pipeline and Planned Commercial Production TORONTO and HAIFA, Israel, Aug. 13, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc [...]
Park Dental Partners Announces Second Quarter 2026 Results
12/08/2026
MINNEAPOLIS, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Park Dental Partners, Inc. (NASDAQ: PARK) and affiliated dental practices (“Park Dental Partners,” “we,” “our,” “us,” or the “Company”) today reported its second quarter [...]
Reviva Reports Second Quarter 2026 Financial Results and Recent Business Highlights
12/08/2026
- U.S. composition of matter patent application filed seeking accelerated review for a new form of brilaroxazine designed to extend patent life and commercial exclusivity through 2046 - - FDA feedback on use of new [...]

Pages